We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
Read MoreHide Full Article
Cigna (CI - Free Report) shares ended the last trading session 6.3% higher at $282.41. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.7% loss over the past four weeks.
Cigna’s recent price movement stems from recovering investor confidence in the prospects of the company after an overreaction by investors to the new resolution targeting pharmacy benefit managers. These provisions were initially feared to impose stringent regulations on the healthcare sector. However, the changes are anticipated to be less severe, and the core business outlook for Cigna remains robust, fueling investor confidence.
The company expects the 2024 EPS to be at least $28.40, which indicates growth of 13.2% from the 2023 reported figure. Strong Evernorth Health Services and Cigna Healthcare segments are expected to buoy Cigna’s results and price performance. However, ongoing monitoring of broader market conditions and regulatory changes will be crucial to determining whether further significant stock gains are possible.
This health insurer is expected to post quarterly earnings of $7.84 per share in its upcoming report, which represents a year-over-year change of +15.5%. Revenues are expected to be $62.88 billion, up 22.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Cigna, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CI going forward to see if this recent jump can turn into more strength down the road.
Cigna is part of the Zacks Medical - HMOs industry. Molina (MOH - Free Report) , another stock in the same industry, closed the last trading session 1.7% higher at $296.59. MOH has returned 3.3% in the past month.
For Molina, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $5.81. This represents a change of +32.7% from what the company reported a year ago. Molina currently has a Zacks Rank of #3 (Hold).
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Cigna (CI) Soars 6.3%: Is Further Upside Left in the Stock?
Cigna (CI - Free Report) shares ended the last trading session 6.3% higher at $282.41. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 17.7% loss over the past four weeks.
Cigna’s recent price movement stems from recovering investor confidence in the prospects of the company after an overreaction by investors to the new resolution targeting pharmacy benefit managers. These provisions were initially feared to impose stringent regulations on the healthcare sector. However, the changes are anticipated to be less severe, and the core business outlook for Cigna remains robust, fueling investor confidence.
The company expects the 2024 EPS to be at least $28.40, which indicates growth of 13.2% from the 2023 reported figure. Strong Evernorth Health Services and Cigna Healthcare segments are expected to buoy Cigna’s results and price performance. However, ongoing monitoring of broader market conditions and regulatory changes will be crucial to determining whether further significant stock gains are possible.
This health insurer is expected to post quarterly earnings of $7.84 per share in its upcoming report, which represents a year-over-year change of +15.5%. Revenues are expected to be $62.88 billion, up 22.9% from the year-ago quarter.
While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.
For Cigna, the consensus EPS estimate for the quarter has been revised marginally lower over the last 30 days to the current level. And a negative trend in earnings estimate revisions doesn't usually translate into price appreciation. So, make sure to keep an eye on CI going forward to see if this recent jump can turn into more strength down the road.
The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Cigna is part of the Zacks Medical - HMOs industry. Molina (MOH - Free Report) , another stock in the same industry, closed the last trading session 1.7% higher at $296.59. MOH has returned 3.3% in the past month.
For Molina, the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $5.81. This represents a change of +32.7% from what the company reported a year ago. Molina currently has a Zacks Rank of #3 (Hold).